共 53 条
[11]
Damiano V.(1998)Pharmacokinetics of anticancer agents in patients with impaired liver function Eur J Cancer 34 33-46
[12]
Carlomagno F.(2006)Cytotoxic anticancer agents and renal impairment study: the challenge remains J Clin Oncol 24 533-6
[13]
Vitagliano D.(2008)The effect of chronic renal failure on drug metabolism and transport Expert Opin Drug Metab Toxicol 4 1065-74
[14]
Guida T.(2005)Drug dosing in chronic kidney disease Med Clin North Am 89 649-87
[15]
Vitagliano D.(2005)Dose adjustment in patients with liver disease Drug Saf 28 529-45
[16]
Carlomagno F.(2008)Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction Eur J Clin Pharmacol 64 1147-61
[17]
Motti M.L.(1976)Prediction of creatinine clearance from serum creatinine Nephron 16 31-41
[18]
Morabito A.(1973)Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 646-9
[19]
Piccirillo M.C.(2006)Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function J Clin Oncol 24 4558-64
[20]
Falasconi F.(2008)Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group J Clin Oncol 26 570-6